Company / Shareholders' Equity
Pfizer Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$86.5B
FY2025
5-year range
$77.2B / $95.7B
FY2021-FY2025
Trend
-2.0%
vs FY2024
Sector context
#1 of 213
Health Care
What the data says
Among 213 Health Care companies, Pfizer is in the top 0% for shareholders' equity. Shareholders' Equity has declined for 3 consecutive years, from $95.7B in FY2022 to $86.5B in FY2025.
Based on SEC 10-K filings.
$86.5B in FY2025 with a 5-year CAGR of +6.5%. Ranks 1st among 213 companies in Health Care.
Declined from $89.0B to $86.5B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -3.3%
- 5-Year CAGR
- +6.5%
- 10-Year CAGR
- -
Sector benchmark
Top 0% in Health CareTop 0% of 213This company $86.5B Sector average $2.5B
▼
+3292.7% above sector average
Key checks
Key Insights
- Pfizer's shareholders' equity has declined for 3 consecutive years.
- 5-year CAGR of +6.5%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 2.0% year-over-year.
- Ranks #1 out of 213 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score 1.09 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $86.5B | -2.0% |
| FY2024 | $88.2B | -0.9% |
| FY2023 | $89.0B | -6.9% |
| FY2022 | $95.7B | +23.9% |
| FY2021 | $77.2B | +22.1% |
| FY2020 | $63.2B | +0.2% |
| FY2019 | $63.1B | -0.4% |
| FY2018 | $63.4B | -11.1% |
| FY2017 | $71.3B | +19.8% |
| FY2016 | $59.5B | -8.0% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026